These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35610460)

  • 1. Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.
    Gaimari A; Fusaroli M; Raschi E; Baldin E; Vignatelli L; Nonino F; De Ponti F; Mandrioli J; Poluzzi E
    Drug Saf; 2022 Jun; 45(6):663-673. PubMed ID: 35610460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System.
    Golomb BA; Verden A; Messner AK; Koslik HJ; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):403-413. PubMed ID: 29427042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
    Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
    Edwards IR; Star K; Kiuru A
    Drug Saf; 2007; 30(6):515-25. PubMed ID: 17536877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyotrophic lateral sclerosis associated with statins. A disproportionality analysis of the WHO Program for International Drug Monitoring database (VigiBase).
    Macías Saint-Gerons D; Castro JL
    Eur J Clin Pharmacol; 2019 Apr; 75(4):587-589. PubMed ID: 30470902
    [No Abstract]   [Full Text] [Related]  

  • 6. Statins and amyotrophic lateral sclerosis--the level of evidence for an association.
    Sørensen HT; Lash TL
    J Intern Med; 2009 Dec; 266(6):520-6. PubMed ID: 19930099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
    Fujimoto M; Hosomi K; Takada M
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.
    Golomb BA; Kwon EK; Koperski S; Evans MA
    Drug Saf; 2009; 32(8):649-61. PubMed ID: 19591530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System.
    Antonazzo IC; Raschi E; Forcesi E; Riise T; Bjornevik K; Baldin E; De Ponti F; Poluzzi E
    Expert Opin Drug Saf; 2018 Sep; 17(9):869-874. PubMed ID: 30058390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing Matters: A Machine Learning Method for the Prioritization of Drug-Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure.
    Battini V; Cocco M; Barbieri MA; Powell G; Carnovale C; Clementi E; Bate A; Sessa M
    Drug Saf; 2024 Sep; 47(9):895-907. PubMed ID: 38687463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database.
    Sessa M; Andersen M
    BioDrugs; 2021 Mar; 35(2):215-227. PubMed ID: 33609278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Signals of COVID-19 as an Effect Modifier of Adverse Drug Reactions.
    Hauben M; Hung E; Chen Y
    Clin Ther; 2024 Jan; 46(1):20-29. PubMed ID: 37919188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Gatti M; Antonazzo IC; Diemberger I; De Ponti F; Raschi E
    Eur J Prev Cardiol; 2021 Aug; 28(9):983-989. PubMed ID: 34402868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system.
    Antonazzo IC; Poluzzi E; Forcesi E; Salvo F; Pariente A; Marchesini G; De Ponti F; Raschi E
    Acta Diabetol; 2020 Jan; 57(1):71-80. PubMed ID: 31203438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Stack TJ; Kim S; Lamb MM; Mohammad I; Zeatoun A; Lopez E; Klatt-Cromwell C; Thorp BD; Ebert CS; Senior BA; Kimple AJ; Alicea D
    ORL J Otorhinolaryngol Relat Spec; 2023; 85(6):329-339. PubMed ID: 37963438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How safe are recently FDA-approved antimicrobials? A review of the FDA adverse event reporting system database.
    Khadem TM; van Manen RP; Brown J
    Pharmacotherapy; 2014 Dec; 34(12):1324-9. PubMed ID: 25421400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database.
    Stamatellos VP; Siafis S; Papazisis G
    Br J Clin Pharmacol; 2021 Dec; 87(12):4769-4779. PubMed ID: 33998034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.